S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
OTCMKTS:EVTCY

Evotec Stock Forecast, Price & News

$104.96
0.00 (0.00 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$104.96
$104.96
50-Day Range
$81.25
$106.10
52-Week Range
$51.80
$106.10
VolumeN/A
Average Volume667 shs
Market Capitalization$8.66 billion
P/E Ratio64.00
Dividend YieldN/A
Beta1.01
30 days | 90 days | 365 days | Advanced Chart
Receive EVTCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.


Evotec logo

About Evotec

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Evotec (OTCMKTS:EVTCY) Frequently Asked Questions

Is Evotec a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Evotec stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVTCY, but not buy additional shares or sell existing shares.
View analyst ratings for Evotec
or view top-rated stocks.

What stocks does MarketBeat like better than Evotec?

Wall Street analysts have given Evotec a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evotec wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Evotec?

Evotec saw a decrease in short interest in August. As of August 31st, there was short interest totaling 100 shares, a decrease of 75.0% from the August 15th total of 400 shares. Based on an average daily trading volume, of 600 shares, the short-interest ratio is presently 0.2 days.
View Evotec's Short Interest
.

When is Evotec's next earnings date?

Evotec is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Evotec
.

How has Evotec's stock been impacted by COVID-19?

Evotec's stock was trading at $49.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVTCY stock has increased by 113.8% and is now trading at $104.96.
View which stocks have been most impacted by COVID-19
.

Who are Evotec's key executives?

Evotec's management team includes the following people:
  • Werner Lanthaler, Chief Executive Officer
  • Craig L. Johnstone, Chief Operating Officer & Member-Management Board
  • Enno Spillner, Chief Financial Officer
  • Cord E. Dohrmann, Chief Scientific Officer
  • Volker Braun, SVP, Head-Investor Relations & ESG

What is Evotec's stock symbol?

Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."

How do I buy shares of Evotec?

Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evotec's stock price today?

One share of EVTCY stock can currently be purchased for approximately $104.96.

How much money does Evotec make?

Evotec has a market capitalization of $8.66 billion and generates $572.16 million in revenue each year.

How many employees does Evotec have?

Evotec employs 3,572 workers across the globe.

What is Evotec's official website?

The official website for Evotec is www.evotec.com.

Where are Evotec's headquarters?

How can I contact Evotec?

Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at (494) 056-0810 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.